Interferon reduces recurrences of basal cell and squamous cell cancers (CROSBI ID 114094)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Ikić, Drago ; Padovan, Ivo ; Pipić, Nedim ; Čajkovac, Vladimir ; Kusić, Zvonko ; Đaković, Nikola ; Gregurek- Novak, Teodora ; Soldo-Belić, Antica ; Spaventi, Šime ; Belicza, Mladen ; Ferenčić, Željko
engleski
Interferon reduces recurrences of basal cell and squamous cell cancers
Interferon is considered to be an important curative agent for dermatologic diseases. We report the follow-up experience of patients with basal cell or squamous cell carcinomas treated with human natural leukocyte interferon. Among 52 patients with basal cell carcinoma treated with HNLI more than 10 years ago, and among 58 treated more than 5 years ago, only 2 recurrences were observed. There were no recurrences in 75 patients who had complete response to HNLI treatment, nor were there any in 20 patients with either a partial or complete response to r.IFM alpha 2c treatment. Of 52 patients with squamous cell carcinoma, 31 had been treated more than 10 years earlier, two recurrences of the disease at the site of the original lesion were observed.
interferon ; basal cell carcinoma ; squamous cell carcinoma
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti